Zhaohui Su, VP of Biostatistics at Ontada, shared a post on LinkedIn:
“Artificial intelligence (AI) is rapidly transforming oncology by improving diagnostics, personalizing treatment, and streamlining clinical trial recruitment. AI adoption is accelerating, with major investments in drug discovery and digital health.
Tools such as ASCO’s Guidelines Assistant, an AI-powered clinical decision support tool, provide oncologists with quick, evidence-based answers to guideline questions. Platforms like OpenEvidence help clinicians interpret research, while imaging solutions from iCAD and PathAI enhance cancer detection and pathology workflows. In precision oncology, companies integrate multimodal data to guide therapy choices and biomarker discovery. AI also expedites trial matching through systems like OncoLens and Deep 6 AI, reducing manual workload and improving patient access.
Backed by multi-billion-dollar investments and growing regulatory support, AI technologies are becoming essential in cancer care across diagnostics, treatment planning, and patient engagement.”
More posts featuring Zhaohui Su on OncoDaily.